

April 24, 2012
Seikagaku Corporation
(Securities Code: 4548)

Seikagaku and Biotie Agree to Terminate the Anti-VAP-1 Monoclonal Antibody License Agreement

Tokyo, Japan—Seikagaku Corporation (head office: Chiyoda-ku, Tokyo) hereby announces that it has jointly agreed with Biotie Therapies Corp. (head office: Turku, Finland) to terminate the licensing agreement concerning human anti-VAP-1 monoclonal antibody (development code: SI-636), as of April 24, 2012, because the therapeutic focus for the product is no longer aligned with Seikagaku's development strategy.

Under the license agreement, signed on April 26, 2003, Seikagaku acquired an exclusive license for the development, import, production, and sale of anti-VAP-1 monoclonal antibody in Japan, Taiwan, Singapore, Australia, and New Zealand. Having focused on inflammatory diseases including rheumatoid arthritis as target diseases, Biotie has been conducting clinical trials in Europe, and Seikagaku has been considering its development strategy and assessing the progress and results of those trials. However, Biotie has recently shifted its therapeutic focus for the anti-VAP-1 monoclonal antibody to fibrotic diseases. Since this change is inconsistent with Seikagaku's development strategy, it has been jointly agreed to terminate the agreement.

Seikagaku focuses its research and development on glycoscience, a field of specialization, with GAGs (glycosaminoglycans) as substances of particular focus. Seikagaku will engage in efficient new drug development with locomotive diseases, ophthalmic diseases, and immune and allergic diseases as target diseases.

#####